Latest news

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent…

Debiopharm’s ADC Research Gains Momentum with Launch of First-In-Human Trial Assessing Debio 1562m in Acute Myeloid Leukemia Patients

Debiopharm And Alkyon Therapeutics Announce Research Collaboration To Advance The Next Generation Of Radioligand Therapies

Debiopharm Ignites Oncology Innovation with Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago

Carb-X Grants Debiopharm An Additional $12.3 Million To Advance Development Of Novel Antibiotic Against Gonorrhea

Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research

Debiopharm to Reveal Insights from their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at The 2025 AACR Conference in…

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s…

Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea